's-Hertogenbosch

• Ulipristal versus surgery for symptomatic uterine fibroids Recruiting
  2024-512602-26-00 6 2024-12-02 Uterine fibroids
• Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study Recruiting
  2024-518878-14-01 6 2024-11-25 Inflammatory bowel disease
• The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlle … Recruiting
  2024-514055-15-00 6 2024-11-19 Pulmonary sarcoidosis
• CHASIT Recruiting
  2024-516940-24-00 4 2024-10-29 locally advanced urothelial cancer.
• Timing of start of systemlc treatment for asymptomatic MEtastasized PANcreatic cancer (TIMEPAN): a prospective multicenter patient preferenc … Recruiting
  2023-509465-20-00 5 2024-10-28 metastatic pancreatic cancer
• DAROTAXEL Recruiting
  2024-516939-28-00 4 2024-10-28 metastatic castration-resistant prostate cancer
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure. Recruiting
  2023-509706-30-00 5 2024-10-18 Heart failure (HF)
• DOSAgE study: A multicenter randomized phase III trial of DOSe-reduced Chemotherapy for Advanced Colorectal Cancer in Older patients Recruiting
  2023-506115-17-00 5 2024-10-14 Metastatic Colorectal Cancer
• A lower dose olaparib, combined with a drug which inhibits olaparib degradation, to increase tolerability and decrease the price of the trea … Recruiting
  2024-516414-38-00 11 2024-10-01 Cancer
• A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s dise … Recruiting
  2024-511110-21-00 1 2024-09-09 Parkinson’s Disease
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly … Recruiting
  2023-505377-32-00 5 2024-08-15 Diffuse large B-cell lymphoma (DLBCL)
• CLEAR-PATH trial Recruiting
  2024-513363-15-01 11 2024-07-22 (Chronic) Peripheral (occlusive) arterial disease (PAD)
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 5 2024-05-14 multiple myeloma
• HOVON 165 CLL: A prospective randomized phase I/II trial of venetoclax treatment (26 cycles) with 6 cycles or 12 cycles of epcoritamab in pa … Recruiting
  2022-500305-40-00 9 2024-04-10 Small Lymphocytic Lymphoma
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• VulVaccin study Recruiting
  2023-506792-94-00 11 2024-03-04 Vulvar High-Grade Squamous Intraepithelial Lesion (vHSIL)
• RECOVERY Recruiting
  2023-507441-29-00 5 2024-02-29 Pneumonia
• PREMI trial Recruiting
  2023-503220-76-01 6 2024-02-13 Unexplained recurrent miscarriages
• Anticoagulation for Stroke Prevention In patients with Recent Episodes of Atrial Fibrillation occurring transiently with stress Recruiting
  2023-509142-35-00 6 2024-01-29 Atrial fibrillation after stress (e.g., noncardiac surgery or acute me
• A study to investigate the effect of adding cobicistat to venetoclax and azacitidine in patients with acute myeloid leukemia (AML) who are i … Recruiting
  2023-505379-61-00 4 2024-01-17 Acute Myeloid Leukaemia
• PEHAB II Recruiting
  2023-507466-40-00 6 2024-01-12 Prostate cancer
• Staphylococcus aureus Network Adaptive Platform trial (SNAP) Recruiting
  2023-503582-35-00 6 2023-10-26 Staphylococcus aureus bacteremia
• (SPARROW) Standard versus Pre-emptive Antibiotic Treatment to Reduce the Rate of Infectious Outcomes after Whipple’s procedure (SPARROW): a … Recruiting
  2024-510766-16-00 11 2023-03-06 Pancreatoduodenectomy with a high risk for contaminated bile
• Renal Lifecycle Trial: A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in … Recruiting
  2023-508389-13-00 5 2022-11-08 Combined endpoint of all-cause mortality, kidney failure, and hospital

Showing 49–72 of 144 trials